A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury

NCT03229031 · clinicaltrials.gov ↗

PHASE3

Phase

SUSPENDED

Status

160

Enrollment

INDUSTRY

Sponsor class

Stopped low recruitment rate

Conditions

Spinal Cord Injuries

Interventions

DRUG: ES135

Sponsor

Eusol Biotech Co., Ltd.